kabutan

FRONTEO surges on AI drug discovery partnership with Astellas Pharma

Fri Apr 17, 2026 9:07 am JST Catalyst

Fronteo Inc <2158> drew heavy buying interest, breaking through its 75-day moving average resistance to reach the upper 800 yen range.

The company, which originated in legal services using proprietary natural language processing AI, has expanded horizontally into AI solutions. Its life sciences and healthcare sectors now serve as major earnings drivers.

After the close on the 16th, Fronteo announced an agreement with Astellas Pharma Inc <4503> regarding target molecule discovery. The partnership will leverage the "Drug Discovery AI Factory" to accelerate early-stage development of innovative drugs, sparking a rally in the shares.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.

Related Articles